Vertex reports positive trial results for acute pain candidate VX-548
Champion of treatments for cystic fibrosis (CF), US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has been moving to diversify its product offerings, and today announced positive results from two Phase II proof-of-concept (POC) studies that investigated treatment with the selective NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery.
This is Vertex’ fourth attempt to develop a sodium channel Nav1.8 inhibitor, after VX-128, VX-150 and VX-961 failed to impress, but the latest attempt did to a certain extent, with the firm’s shares up 1.7% at $260.97 on Thursday.
Pain represents Vertex’ bid to go beyond it CF comfort zone, but Stifel analysts cautioned that the area might not fit into the company’s high-margin business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze